Rheos Medicines Inc. came out of stealth mode on March 22 with $60m in Series A venture capital from Third Rock Ventures to fund the development of precision medicines for autoimmune and inflammatory diseases and cancer based on the company's insights into immune cell metabolism - though it will seek partners to move ahead with cancer programs.
Cambridge, Mass.-based Rheos is building a drug discovery and biomarker identification platform that includes its proprietary Immune Cell Encyclopedia (ICE),...






